Investment
Features
FeesSafety
Academy
More
Pluang+

Global X Russell 2000 Covered Call ETF remains a Buy with ~12% yield via aggressive option income in flat or volatile markets.

Analyst Insights
20 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

The Global X Russell 2000 Covered Call ETF (RYLD) continues to be recommended as a Buy due to its strategy of writing at-the-money calls on the Russell 2000, generating about a 12% trailing twelve months yield. While RYLD has underperformed the Russell 2000 index during strong rallies, it excels in flat or slightly down small-cap markets by producing high option income and mitigating moderate drawdowns. The ETF is expected to perform well if small-cap markets remain range-bound or face mild pressure, offering potential annual returns of 5–10% from option premiums. The main risk remains sharp small-cap drawdowns, but the ETF’s aggressive option strategy and relative valuations position it well for alpha if markets stabilize or mean revert.

More News

Investors in Putnam mutual funds may claim losses in a new class action lawsuit.

Investors in Putnam mutual funds may claim losses in a new class action lawsuit.

The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...

Market News
Bearish
24 minutes ago
Stocks fall sharply due to legal probes, financing plans, and volatile listings today.

Stocks fall sharply due to legal probes, financing plans, and volatile listings today.

Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...

Market News
Bearish
1 hour ago
Study finds 2 years of lenalidomide maintenance as effective as indefinite treatment for multiple myeloma.

Study finds 2 years of lenalidomide maintenance as effective as indefinite treatment for multiple myeloma.

The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...

Company Fundamentals
Neutral
1 hour ago
Stock market jumps on strong corporate news and high trading volumes in EV and green energy sectors

Stock market jumps on strong corporate news and high trading volumes in EV and green energy sectors

The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...

Market News
Bullish
1 hour ago
Akamai officer sells shares amid shift to cloud and cybersecurity growth

Akamai officer sells shares amid shift to cloud and cybersecurity growth

An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...

Market News
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App